House Bill No. 622, introduced by Representative Hilferty, mandates health insurance coverage for histotripsy procedures used in the treatment of liver cancer when deemed medically necessary. The bill outlines specific conditions under which coverage is required, including residual disease after chemotherapy, metastatic colorectal cancer where surgery is not viable, tumors up to four centimeters, and metastatic neuroendocrine tumors with elevated hormone levels. Additionally, the bill applies to Medicaid coverage, ensuring that eligible individuals receive the same benefits. It also allows health plans to impose annual deductibles, coinsurance, and copayments consistent with their established terms.

The legislation defines "histotripsy" as a non-invasive procedure utilizing high-intensity sound waves to destroy cancer tissue in the liver. It requires health maintenance organizations and managed care organizations that contract with the state to provide documentation regarding treatment for rare cancers. The provisions of this act will apply to new health coverage plans issued on or after January 1, 2026, and existing plans must comply by their renewal date, but no later than January 1, 2027.